Moderna-Merck mRNA vaccine with Keytruda cuts skin cancer recurrence by 44%

The risk of recurrence of deadly skin cancer was reduced by nearly half when patients were treated with an mRNA vaccine developed by Moderna and Merck Co. and the immunotherapy Keytruda drug, according to a new study.
Source: Health News - UPI.com - Category: Consumer Health News Source Type: news